SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2016
Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- Five-year follow-up of the OptiTrain trial on concurrent resistance and high-intensity interval training during chemotherapy for patients with breast cancer.Scientific reports · 2024Trial
- Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement (OPERA®) for aromatase inhibitors-related arthralgia management (AIA): a prospective phase II trial (NCT04161833).Medical oncology (Northwood, London, England) · 2022Trial
- A prospective multi-centre, randomized study comparing the addition of tapering dexamethasone to other standard of care therapies for taxane-associated pain syndrome (TAPS) in breast cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Trial
- Trial
- Supercritical COPharmaceutics · 2026Article
- Mechanism-based management of taxane-induced neuropathic pain in breast cancer survivors: a critical review.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Celecoxib pretreatment and nab-paclitaxel-associated acute pain syndrome in patients with breast cancer: a prospective, non-randomized controlled clinical study.International journal of surgery (London, England) · 2026Article
- Factors associated with taxane-associated acute pain syndrome in pancreatic cancer patients receiving gemcitabine and nab-paclitaxel.Discover oncology · 2025Article
- Potential of histone deacetylase 6 inhibitors in alleviating chemotherapy-induced peripheral neuropathy.The Korean journal of pain · 2025Article
- Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management.Current treatment options in oncology · 2025Review
- Nab-paclitaxel versus paclitaxel for taxane acute pain syndrome in solid tumors: a systematic review and meta-analysis.Frontiers in oncology · 2025Article
- Dexamethasone dose-dependently prevents taxane-associated acute pain syndrome in breast cancer treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Pain associated with breast cancer: etiologies and therapies.Frontiers in pain research (Lausanne, Switzerland) · 2023Review
- Article
- Integrating Systematic Reviews into Supportive Care Trial Design: The Rethinking Clinical Trials (REaCT) Program.Current oncology (Toronto, Ont.) · 2022Review
- Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design.Current oncology (Toronto, Ont.) · 2021Review
- Interventional Therapies for Pain in Cancer Patients: a Narrative Review.Current pain and headache reports · 2021Review
- Herbal Prescription SH003 Alleviates Docetaxel-Induced Neuropathic Pain in C57BL/6 Mice.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTaxane acute pain syndrome (TAPS) is characterized by myalgias and arthralgias starting 24-48 h after taxane-based chemotherapy and lasting for 5-7 days. Relatively little is known about its incidence and impact on quality of life.
objectivesA systematic review was conducted evaluating the incidence of TAPS in breast cancer patients receiving taxane-based chemotherapy.
methodsEmbase, Cochrane, and Ovid MEDLINE were searched from 1947 to July 2015. Data was sought from randomized controlled trials (RCTs), prospective and retrospective observational studies. Two reviewers independently screened citations and full text articles. Outcomes of interest were the incidence of TAPS and its impact on quality of life.
resultsOf 980 citations identified, 51 relevant studies (27,007 patients) were included. Data came from RCTs (12,357 patients), retrospective (6566 patients) and prospective observational studies (6210 patients). Study sample sizes ranged from 14 to 4149 patients (median 152). Given the significance between study heterogeneity, a meta-analysis was not performed. The incidence of TAPS varied between taxanes: paclitaxel (median 13.1 %, range 0.9-86 %), docetaxel (median 10.5 %, range 3.6-70 %), and nab-paclitaxel (26 %, range 14-43 %). In the metastatic setting, median incidence was 30 % (range 5.4-73 %), compared with 11.3 % (range 0.9-86 %) in the adjuvant setting. Three out of eight studies assessing quality of life demonstrated pain interference with daily activities.
conclusionsThe incidence of TAPS varies between taxanes, regimens, and disease settings. In order to identify patients at the greatest risk of TAPS, and hence optimize its prevention and management, standardized methods of diagnosing and measuring TAPS are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.